A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome

TL;DR: These findings provide strong evidence that KRIS proteins contribute to the inflammatory process underlying end-stage renal disease development in both types of diabetes, and point to new therapeutic targets and new prognostic tests to identify subjects at risk of end-Stage renal disease.

TL;DR: IL-1β inhibition with canakinumab reduces major adverse cardiovascular event rates among high-risk atherosclerosis patients with CKD, particularly among those with a robust anti-inflammatory response to initial treatment.

TL;DR: The success of targeting molecular pathways identified through approaches that involve the integration of various datasets has been demonstrated in clinical trials and puts nephrology in a position to test the concept of precision medicine.

TL;DR: Deconvolution analysis of the RNA sequencing data set indicated a significant increase in monocytes, fibroblasts, and myofibroBLasts in advanced DN kidneys, which provides potential molecular mechanisms for DN progression and association of differential gene expression with the functional and structural changes observed in patients with early and advanced DN.

TL;DR: The canonical complement signaling pathway was determined to be statistically differentially regulated in both DKD glomeruli and tubuli and was associated with increased glomerulosclerosis even in a different set of DKD samples.

TL;DR: The authors demonstrated that the amount of EGF in the urine is just as useful, providing a biomarker that can be easily tracked over time without requiring invasive biopsies, and identified uEGF as an independent risk predictor of CKD progression.

TL;DR: It is proposed that careful targeting of TLR2, TLR4, and NLRP3 signalling pathways could be beneficial for the treatment of diabetes mellitus and diabetic nephropathy.

TL;DR: After the development of persistent microalbuminuria, progression and regression of kidney disease each commonly occur and intensive glycemic control, lower blood pressure, and a more favorable lipid profile are associated with improved outcomes.